Patents Assigned to Genentech
  • Inhibitors of angiopoietin-like 4 protein, combinations, and their use
    Publication number: 20070026002
    Abstract: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Hanspeter Gerber, Napoleone Ferrara, Xiao Liang
  • APO-2 ligand-anti-her-2 antibody synergism
    Publication number: 20070026001
    Abstract: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Gail Phillips
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20070025999
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mass, William Novotny
  • Human growth hormone aqueous formulation
    Publication number: 20070027083
    Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Barbara O'Connor, James Oeswein
  • Use of VEGF For Treating Bone Defects
    Publication number: 20070026044
    Abstract: The present invention provides pharmaceutical compositions comprising VEGF or variants thereof for promoting bone formation, in vitro and in vivo. Methods of using those compositions are also provided. Compositions and methods of the present invention can be used for promoting and improving the repair process in subjects with bone defects.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Stuart Bunting, Richard Carano, Ellen Filvaroff, Richard Gosselin, Franklin Peale
  • APO-2L receptor agonist and CPT-11 synergism
    Publication number: 20070026000
    Abstract: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Mark Benyunes, Ralph Schwall
  • Process for Producing Polypeptides
    Publication number: 20070026496
    Abstract: A process is described for producing a polypeptide heterologous to E. coli wherein E. coli cells comprising nucleic acid encoding the polypeptide are cultured in a culture medium while feeding to the culture medium a transportable organophosphate, such that the nucleic acid is expressed. The polypeptide is then recovered from the cells.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Woon-Lam Leung, James Swartz
  • Method for Treating Lupus
    Publication number: 20070025988
    Abstract: A method of treating lupus in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens and an article of manufacture therefor.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventor: Paul Brunetta
  • METHODS FOR ENHANCING THE EFFICACY OF CANCER THERAPY
    Publication number: 20070025998
    Abstract: The invention concerns the identification of tumor antigens the expression of which is selectively upregulated by retinoid treatment. The invention further concerns improved methods of cancer treatment and, in particular, methods enhancing the efficacy of the treatment of cancers characterized by aberrant Wnt signaling by administration of retinoic acid or other retinoids.
    Type: Application
    Filed: July 18, 2006
    Publication date: February 1, 2007
    Applicant: Genentech Inc,
    Inventors: Diane Pennica, Paul Polakis, Wayne Szeto, David Tice
  • Method for Treating Vasculitis
    Publication number: 20070025987
    Abstract: A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of one to three doses within a period of about one month. Another method of treating ANCA-associated vasculitis in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens. Further provided are articles of manufacture useful for such methods.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventor: Paul Brunetta
  • PRO1017 nucleic acids
    Patent number: 7169912
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: January 30, 2007
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • PRO211 polypeptides
    Patent number: 7169906
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: January 30, 2007
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Anti-VEGF antibodies
    Patent number: 7169901
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: January 30, 2007
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Purification of polypeptides
    Patent number: 7169908
    Abstract: A method for purifying a desired heterologous polypeptide from microbial fermentation broth or homogenate in which it is produced and solubilized is described. This method involves adding to the broth or homogenate an effective amount of a solution of 6,9-diamino-2-ethoxyacridine lactate (ethacridine lactate) to precipitate host cell impurities under conditions wherein the majority of polypeptide remains soluble, and separating the desired polypeptide from the broth or homogenate. The broth or homogenate containing the ethacridine lactate and polypeptide is also disclosed.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: January 30, 2007
    Assignee: Genentech, Inc.
    Inventors: Philip M. Lester, Josefine Persson
  • TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA INHIBITORS
    Publication number: 20070020268
    Abstract: The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-? inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
    Type: Application
    Filed: July 27, 2006
    Publication date: January 25, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Rebecca Ward
  • Wound Healing
    Publication number: 20070021342
    Abstract: Methods for accelerating and/or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided.
    Type: Application
    Filed: September 25, 2006
    Publication date: January 25, 2007
    Applicant: Genentech, Inc.
    Inventors: Timothy Breen, Stuart Bunting, Charles Semba
  • Anti-VEGF antibodies
    Publication number: 20070020267
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: April 27, 2006
    Publication date: January 25, 2007
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev Sidhu, Christian Wiesmann
  • GLYCOPROTEIN COMPOSITIONS
    Publication number: 20070020260
    Abstract: The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.
    Type: Application
    Filed: September 28, 2006
    Publication date: January 25, 2007
    Applicant: Genentech, Inc.
    Inventor: Leonard Presta
  • Prokaryotically produced antibodies and uses thereof
    Publication number: 20070020725
    Abstract: The present invention provides methods and compositions for improved expression and production of recombinant antibodies in prokaryotic expression systems. Particularly contemplated are prokaryotic expression and production of full length aglycosylated antibodies. The antibody products of the invention can be used in various aspects of biological research, diagnosis and medical treatment.
    Type: Application
    Filed: May 22, 2006
    Publication date: January 25, 2007
    Applicant: GENENTECH, INC.
    Inventors: Laura Simmons, Laura Klimowski, Dorothea Reilly, Daniel Yansura
  • Human tPA production using vectors coding for DHFR protein
    Patent number: H2181
    Abstract: A method for producing tissue plasminogen activator (t-PA) in eukaryotic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild-type DHFR with methotrexate.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: February 6, 2007
    Assignee: Genentech, Inc.
    Inventors: Arthur D. Levinson, Diane Pennica, William J. Kohr, Gordon A. Vehar, David V. Goeddel, Elizabeth M. Yelverton, Christian C. Simonsen